相似文献
1
Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series.
Rheumatology (Oxford). 2021 Nov 3;60(11):e387-e388. doi: 10.1093/rheumatology/keab421.
2
Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.
JAMA Dermatol. 2016 Aug 1;152(8):944-5. doi: 10.1001/jamadermatol.2016.0866.
3
Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.
J Autoimmun. 2019 Jun;100:131-136. doi: 10.1016/j.jaut.2019.03.003. Epub 2019 Mar 9.
4
Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis.
J Am Acad Dermatol. 2012 Oct;67(4):e167-8. doi: 10.1016/j.jaad.2012.01.015.
5
Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody.
Eur Respir Rev. 2015 Jun;24(136):370-2. doi: 10.1183/16000617.00006714.
6
Anti-NXP2 antibody-associated extensive subcutaneous calcinosis in adult-onset myositis.
Rheumatology (Oxford). 2017 Oct 1;56(10):1661. doi: 10.1093/rheumatology/kex210.
7
Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options.
Clin Exp Rheumatol. 2017 Mar-Apr;35(2):303-308. Epub 2016 Nov 14.
8
An Unusual Cause of Dysphagia.
Gastroenterology. 2020 May;158(6):e3-e5. doi: 10.1053/j.gastro.2019.11.016. Epub 2019 Nov 16.
9
Systemic Calcinosis in NXP2-Dermatomyositis.
J Clin Rheumatol. 2019 Jun;25(4):e35. doi: 10.1097/RHU.0000000000000641.
10
Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.
Mod Rheumatol Case Rep. 2021 Jan;5(1):76-81. doi: 10.1080/24725625.2020.1816674. Epub 2020 Sep 14.
引用本文的文献
1
Calcinosis Universalis: An Atypical Presentation of Mi-2 Positive Juvenile Dermatomyositis - A Case-Based Review.
Mediterr J Rheumatol. 2025 Jun 2;36(2):308-315. doi: 10.31138/mjr.291024.cua. eCollection 2025 Jun.
2
Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis.
Clin Exp Rheumatol. 2025 Jul 25. doi: 10.55563/clinexprheumatol/35pbbq.
3
Utility of Myositis-Specific Autoantibodies for Treatment Selection in Myositis.
Curr Treatm Opt Rheumatol. 2022 Dec;8(4):105-116. doi: 10.1007/s40674-022-00198-1. Epub 2022 Sep 28.
4
Ectopic calcifications in the musculoskeletal field: the basis for preventive and curative pharmacological strategies.
Clin Rheumatol. 2025 Mar;44(3):869-886. doi: 10.1007/s10067-025-07335-w. Epub 2025 Jan 24.
5
The role of hypoxic microenvironment in autoimmune diseases.
Front Immunol. 2024 Nov 7;15:1435306. doi: 10.3389/fimmu.2024.1435306. eCollection 2024.
6
Treatment of Calcinosis in Dermatomyositis-Case Report and Review.
J Clin Med. 2024 Oct 18;13(20):6234. doi: 10.3390/jcm13206234.
7
Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons.
Expert Opin Pharmacother. 2024 Aug;25(12):1625-1645. doi: 10.1080/14656566.2024.2392021. Epub 2024 Aug 18.
8
Calcinosis in dermatomyositis.
Curr Opin Rheumatol. 2024 Nov 1;36(6):453-458. doi: 10.1097/BOR.0000000000001036. Epub 2024 Aug 9.
9
Treatment of calcinosis cutis associated with autoimmune connective tissue diseases.
Arch Dermatol Res. 2024 Jun 15;316(7):390. doi: 10.1007/s00403-024-03148-0.
10
Effectiveness of generic tofacitinib in idiopathic inflammatory myositis (IIM)-a retrospective analysis from Indian Myositis Registry (MyoIN).
Clin Rheumatol. 2024 Jul;43(7):2245-2252. doi: 10.1007/s10067-024-07019-x. Epub 2024 Jun 3.
本文引用的文献
1
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
Arthritis Rheumatol. 2021 May;73(5):858-865. doi: 10.1002/art.41602. Epub 2021 Mar 24.
2
Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.
Brain. 2019 Nov 1;142(11):e59. doi: 10.1093/brain/awz293.
3
Calcinosis cutis complicating adult-onset dermatomyositis.
Arch Dermatol. 2004 Mar;140(3):365-6. doi: 10.1001/archderm.140.3.365.
4
Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification.
J Pediatr. 1983 Dec;103(6):882-8. doi: 10.1016/s0022-3476(83)80706-9.
5
Patterns of calcification in childhood dermatomyositis.
AJR Am J Roentgenol. 1984 Feb;142(2):397-400. doi: 10.2214/ajr.142.2.397.
Zotero 插件